|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ungureanu A, Zlatian O, Mitroi G, Drocas
A, Ţîrcă T, Calina D, Dehelean C, Docea AO, Izotov BN, Rakitskii
VN, et al: Staphylococcus aureus colonisation in patients from a
primary regional hospital. Mol Med Rep. 16:8771–8780. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zlatian O, Balasoiu AT, Balasoiu M,
Cristea O, Docea AO, Mitrut R, Spandidos DA, Tsatsakis AM, Bancescu
G and Calina D: Antimicrobial resistance in bacterial pathogens
among hospitalised patients with severe invasive infections. Exp
Ther Med. 16:4499–4510. 2018.PubMed/NCBI
|
|
4
|
Tanase A, Colita A, Ianosi G, Neagoe D,
Branisteanu DE, Calina D, Docea AO, Tsatsakis A and Ianosi SL: Rare
case of disseminated fusariosis in a young patient with graft vs.
host disease following an allogeneic transplant. Exp Ther Med.
12:2078–2082. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Călina D, Roşu L, Roşu AF, Ianoşi G,
Ianoşi S, Zlatian O, Mitruţ R, Docea AO, Rogoveanu O, Mitruţ P, et
al: Etiological diagnosis and pharmacotherapeutic management of
parapneu-monic pleurisy. Farmacia. 64:946–952. 2016.
|
|
6
|
Travis WD: Pathology of lung cancer. Clin
Chest Med. 32:669–692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paik PK, Shen R, Berger MF, Ferry D, Soria
JC, Mathewson A, Rooney C, Smith NR, Cullberg M, Kilgour E, et al:
A phase Ib open-label multicenter study of AZD4547 in patients with
advanced squamous cell lung cancers. Clin Cancer Res. 23:5366–5373.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nogova L, Sequist LV, Perez Garcia JM,
Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge
DR, Schuler M, et al: Evaluation of BGJ398, a fibroblast growth
factor receptor 1-3 kinase inhibitor, in patients with advanced
solid tumors harboring genetic alterations in fibroblast growth
factor receptors: Results of a global phase I, dose-escalation and
dose-expansion study. J Clin Oncol. 35:157–165. 2017. View Article : Google Scholar
|
|
9
|
Yoshioka H, Katakami N, Okamoto H, Iwamoto
Y, Seto T, Takahashi T, Sunaga N, Kudoh S, Chikamori K, Harada M,
et al: A randomized, open-label, phase III trial comparing
amrubicin versus docetaxel in patients with previously treated
non-small-cell lung cancer. Ann Oncol. 28:285–291. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Petta V, Gkiozos I, Strimpakos A and
Syrigos K: Histones and lung cancer: Are the histone deacetylases a
promising therapeutic target? Cancer Chemother Pharmacol.
72:935–952. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miyanaga A, Gemma A, Noro R, Kataoka K,
Matsuda K, Nara M, Okano T, Seike M, Yoshimura A, Kawakami A, et
al: Antitumor activity of histone deacetylase inhibitors in
non-small cell lung cancer cells: Development of a molecular
predictive model. Mol Cancer Ther. 7:1923–1930. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun L, He Q, Tsai C, Lei J, Chen J, Vienna
Makcey L and Coy DH: HDAC inhibitors suppressed small cell lung
cancer cell growth and enhanced the suppressive effects of
receptor-targeting cyto-toxins via upregulating somatostatin
receptor II. Am J Transl Res. 10:545–553. 2018.
|
|
13
|
You BR and Park WH: Down-regulation of
thioredoxin1 is involved in death of calu-6 lung cancer cells
treated with suberoyl bishydroxamic acid. J Cell Biochem.
117:1250–1261. 2016. View Article : Google Scholar
|
|
14
|
Reid T, Valone F, Lipera W, Irwin D,
Paroly W, Natale R, Sreedharan S, Keer H, Lum B, Scappaticci F and
Bhatnagar A: Phase II trial of the histone deacetylase inhibitor
pivaloyloxy-methyl butyrate (Pivanex, AN-9) in advanced non-small
cell lung cancer. Lung Cancer. 45:381–386. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Traynor AM, Dubey S, Eickhoff JC, Kolesar
JM, Schell K, Huie MS, Groteluschen DL, Marcotte SM, Hallahan CM,
Weeks HR, et al: Vorinostat (NSC# 701852) in patients with relapsed
non-small cell lung cancer: A wisconsin oncology network phase II
study. J Thorac Oncol. 4:522–526. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schneider BJ, Kalemkerian GP, Bradley D,
Smith DC, Egorin MJ, Daignault S, Dunn R and Hussain M: Phase I
study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852)
in combination with docetaxel in patients with advanced and
relapsed solid malignancies. Invest New Drugs. 30:249–257. 2012.
View Article : Google Scholar
|
|
17
|
Ramalingam SS, Maitland ML, Frankel P,
Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I,
Vokes EE, Gandara DR and Belani CP: Carboplatin and paclitaxel in
combination with either vorinostat or placebo for first-line
therapy of advanced non-small-cell lung cancer. J Clin Oncol.
28:56–62. 2010. View Article : Google Scholar
|
|
18
|
Shindoh N, Mori M, Terada Y, Oda K, Amino
N, Kita A, Taniguchi M, Sohda KY, Nagai K, Sowa Y, et al: YM753, a
novel histone deacetylase inhibitor, exhibits antitumor activity
with selective, sustained accumulation of acetylated histones in
tumors in the WiDr xenograft model. Int J Oncol. 32:545–555.
2008.PubMed/NCBI
|
|
19
|
Ono H, Iizumi Y, Goi W, Sowa Y, Taguchi T
and Sakai T: Ribosomal protein S3 regulates XIAP expression
independently of the NF-κB pathway in breast cancer cells. Oncol
Rep. 38:3205–3210. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Salvatorelli E, Menna P, Gonzalez Paz O,
Surapaneni S, Aukerman SL, Chello M, Covino E, Sung V and Minotti
G: Pharmacokinetic characterization of amrubicin cardiac safety in
an ex vivo human myocardial strip model. II. Amrubicin shows
metabolic advantages over doxorubicin and epirubicin. J Pharmacol
Exp Ther. 341:474–483. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Petruccelli LA, Dupéré-Richer D,
Pettersson F, Retrouvey H, Skoulikas S and Miller WH Jr: Vorinostat
induces reactive oxygen species and DNA damage in acute myeloid
leukemia cells. PLoS One. 6:e209872011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
You BR and Park WH: Trichostatin A induces
apoptotic cell death of HeLa cells in a Bcl-2 and oxidative
stress-dependent manner. Int J Oncol. 42:359–366. 2013. View Article : Google Scholar
|
|
23
|
You BR, Kim SH and Park WH: Reactive
oxygen species, glutathione, and thioredoxin influence suberoyl
bishydroxamic acid-induced apoptosis in A549 lung cancer cells.
Tumour Biol. 36:3429–3439. 2015. View Article : Google Scholar
|
|
24
|
Han BR, You BR and Park WH: Valproic acid
inhibits the growth of HeLa cervical cancer cells via
caspase-dependent apoptosis. Oncol Rep. 30:2999–3005. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoshioka T, Yogosawa S, Yamada T, Kitawaki
J and Sakai T: Combination of a novel HDAC inhibitor OBP-801/YM753
and a PI3K inhibitor LY294002 synergistically induces apoptosis in
human endometrial carcinoma cells due to increase of Bim with
accumulation of ROS. Gynecol Oncol. 129:425–432. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamada T, Horinaka M, Shinnoh M, Yoshioka
T, Miki T and Sakai T: A novel HDAC inhibitor OBP-801 and a PI3K
inhibitor LY294002 synergistically induce apoptosis via the
suppression of survivin and XIAP in renal cell carcinoma. Int J
Oncol. 43:1080–1086. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ono H, Sowa Y, Horinaka M, Iizumi Y,
Watanabe M, Morita M, Nishimoto E, Taguchi T and Sakai T: The
histone deacetylase inhibitor OBP-801 and eribulin synergistically
inhibit the growth of triple-negative breast cancer cells with the
suppression of survivin, Bcl-xL, and the MAPK pathway. Breast
Cancer Res Treat. 171:43–52. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ichijo H, Nishida E, Irie K, ten Dijke P,
Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K and Gotoh
Y: Induction of apoptosis by ASK1, a mammalian MAPKKK that
activates SAPK/JNK and p38 signaling pathways. Science. 275:90–94.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tai LM, Holloway KA, Male DK, Loughlin AJ
and Romero IA: Amyloid-beta-induced occludin down-regulation and
increased permeability in human brain endothelial cells is mediated
by MAPK activation. J Cell Mol Med. 14:1101–1112. 2010.
|
|
30
|
Chen YY, Liu FC, Chou PY, Chien YC, Chang
WS, Huang GJ, Wu CH and Sheu MJ: Ethanol extracts of fruiting
bodies of antrodia cinnamomea suppress CL1-5 human lung
adenocarcinoma cells migration by inhibiting matrix
metalloproteinase-2/9 through ERK, JNK, p38, and PI3K/Akt signaling
pathways. Evid Based Complement Alternat Med.
2012:3784152012.PubMed/NCBI
|
|
31
|
Noguchi T, Takeda K, Matsuzawa A, Saegusa
K, Nakano H, Gohda J, Inoue J and Ichijo H: Recruitment of tumor
necrosis factor receptor-associated factor family proteins to
apoptosis signal-regulating kinase 1 signalosome is essential for
oxidative stress-induced cell death. J Biol Chem. 280:37033–37040.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Saxena G, Chen J and Shalev A:
Intracellular shuttling and mitochondrial function of
thioredoxin-interacting protein. J Biol Chem. 285:3997–4005. 2010.
View Article : Google Scholar :
|
|
33
|
Hatakeyama Y, Kobayashi K, Nagano T,
Tamura D, Yamamoto M, Tachihara M, Kotani Y and Nishimura Y:
Synergistic effects of pemetrexed and amrubicin in non-small cell
lung cancer cell lines: Potential for combination therapy. Cancer
Lett. 343:74–79. 2014. View Article : Google Scholar
|
|
34
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Del Bufalo D, Desideri M, De Luca T, Di
Martile M, Gabellini C, Monica V, Busso S, Eramo A, De Maria R,
Milella M and Trisciuoglio D: Histone deacetylase inhibition
synergistically enhances pemetrexed cytotoxicity through induction
of apoptosis and autophagy in non-small cell lung cancer. Mol
Cancer. 13:2302014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu Y, Xing K, Badamas R, Kuszynski CA, Wu
H and Lou MF: Overexpression of thioredoxin-binding protein 2
increases oxidation sensitivity and apoptosis in human lens
epithelial cells. Free Radic Biol Med. 57:92–104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Scherpereel A, Berghmans T, Lafitte JJ,
Colinet B, Richez M, Bonduelle Y, Meert AP, Dhalluin X, Leclercq N,
Paesmans M, et al: Valproate-doxorubicin: Promising therapy for
progressing mesothelioma. A phase II study Eur Respir J.
37:129–135. 2011.
|
|
41
|
Suzuki T, Minamide S, Iwasaki T, Yamamoto
H and Kanda H: Cardiotoxicity of a new anthracycline derivative
(SM-5887) following intravenous administration to rabbits:
Comparative study with doxorubicin. Invest New Drugs. 15:219–225.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Noda T, Watanabe T, Kohda A, Hosokawa S
and Suzuki T: Chronic effects of a novel synthetic anthracycline
derivative (SM-5887) on normal heart and doxorubicin-induced
cardiomyopathy in beagle dogs. Invest New Drugs. 16:121–128. 1998.
View Article : Google Scholar : PubMed/NCBI
|
